1. Home
  2. AUPH
  3. AUPH News

Latest Aurinia Pharmaceuticals Inc (AUPH) News on September 11, 2025

Dianthus Therapeutics Stock Earns RS Rating Upgrade
AUPH

Investor's Business Daily

2 days ago

Dianthus Therapeutics Stock Earns RS Rating Upgrade

With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns
AUPH

Simply Wall St.

3 months ago

With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
AUPH

Zacks

3 months ago

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
AUPH

Business Wire

4 months ago

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Is Even Better Than Its Earnings Suggest
AUPH

Simply Wall St.

4 months ago

Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Is Even Better Than Its Earnings Suggest

Aurinia Pharmaceuticals Inc. Just Recorded A 60% EPS Beat: Here's What Analysts Are Forecasting Next
AUPH

Simply Wall St.

4 months ago

Aurinia Pharmaceuticals Inc. Just Recorded A 60% EPS Beat: Here's What Analysts Are Forecasting Next

Company News for May 13, 2025
AUPH

Zacks

4 months ago

Company News for May 13, 2025

AUPH

GuruFocus.com

4 months ago

Aurinia Pharmaceuticals Inc (AUPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates
AUPH

Zacks

4 months ago

Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates

AUPH

MT Newswires

4 months ago

Aurinia Pharmaceuticals' Q1 Swings to Profit, Revenue Rises; Reiterates 2025 Revenue Guidance

AUPH

Associated Press Finance

4 months ago

Aurinia: Q1 Earnings Snapshot

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
AUPH

Business Wire

4 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
AUPH

Business Wire

4 months ago

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting
AUPH

Business Wire

4 months ago

Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting
AUPH

Business Wire

4 months ago

ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
AUPH

Zacks

5 months ago

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
AUPH

Zacks

5 months ago

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

High Growth Tech Stocks To Watch In The US Market
AUPH

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In The US Market

Declining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)?
AUPH

Simply Wall St.

5 months ago

Declining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)?

Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March
AUPH

Insider Monkey

6 months ago

Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?
AUPH

Zacks

6 months ago

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

Signet Jewelers, Big Bear, and More Stocks See Action From Activist Investors
AUPH

Barrons.com

6 months ago

Signet Jewelers, Big Bear, and More Stocks See Action From Activist Investors

Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point
AUPH

Simply Wall St.

6 months ago

Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point

Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock?
AUPH

Zacks

6 months ago

Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock?

Results: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
AUPH

Simply Wall St.

6 months ago

Results: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

AUPH

MT Newswires

6 months ago

RBC Lowers Price Target on Aurinia Pharmaceuticals to $8 From $9, Keeps Outperform, Speculative Risk

Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations
AUPH

Simply Wall St.

6 months ago

Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations

AUPH

GuruFocus.com

6 months ago

Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

AUPH

MT Newswires

6 months ago

Aurinia Pharmaceuticals Swings to Q4 Earnings, Revenue Rises

Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates
AUPH

Zacks

6 months ago

Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates

AUPH

Associated Press Finance

6 months ago

Aurinia: Q4 Earnings Snapshot

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
AUPH

Business Wire

6 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

High Growth Tech Stocks In The United States Spotlighting Three Leaders
AUPH

Simply Wall St.

7 months ago

High Growth Tech Stocks In The United States Spotlighting Three Leaders

Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now?
AUPH

Insider Monkey

7 months ago

Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now?

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
AUPH

Business Wire

7 months ago

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?
AUPH

Zacks

7 months ago

Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?

Aurinia (AUPH) Upgraded to Buy: Here's Why
AUPH

Zacks

8 months ago

Aurinia (AUPH) Upgraded to Buy: Here's Why

Exploring Three High Growth Tech Stocks In The United States
AUPH

Simply Wall St.

9 months ago

Exploring Three High Growth Tech Stocks In The United States

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
AUPH

Zacks

9 months ago

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

AUPH

MT Newswires

9 months ago

Aurinia Pharmaceuticals Insider Bought Shares Worth $10,822,000, According to a Recent SEC Filing

While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership
AUPH

Simply Wall St.

9 months ago

While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
AUPH

Business Wire

10 months ago

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
AUPH

Business Wire

10 months ago

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Aurinia to Participate in Jefferies London Healthcare Conference
AUPH

Business Wire

10 months ago

Aurinia to Participate in Jefferies London Healthcare Conference

AUPH

MT Newswires

10 months ago

RBC Adjusts Aurinia Pharmaceuticals' Price Target to $9 From $8, Keeps Outperform Speculative Risk Rating

Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets
AUPH

Pharmaceutical Technology

10 months ago

Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets

Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring
AUPH

TipRanks

10 months ago

Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring

AUPH

GuruFocus.com

10 months ago

Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

AUPH

MT Newswires

10 months ago

Aurinia Pharmaceuticals Reports Q3 Beat, Plans to Cut Workforce by 45%; Shares Rise

Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates
AUPH

Zacks

10 months ago

Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates

AUPH

Associated Press Finance

10 months ago

Aurinia: Q3 Earnings Snapshot

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
AUPH

Business Wire

10 months ago

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
AUPH

Business Wire

10 months ago

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago
AUPH

Simply Wall St.

10 months ago

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
AUPH

Business Wire

10 months ago

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
AUPH

Business Wire

a year ago

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability
AUPH

Simply Wall St.

a year ago

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability

AUPH

MT Newswires

a year ago

Aurinia Pharmaceuticals Says Lupus Nephritis Treatment Gets Japan's Approval

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
AUPH

Business Wire

a year ago

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
AUPH

Business Wire

a year ago

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

AUPH

GuruFocus.com

a year ago

Significant Acquisition by TANG CAPITAL MANAGEMENT LLC in Aurinia Pharmaceuticals Inc

Aurinia Announces Board Restructuring
AUPH

Business Wire

a year ago

Aurinia Announces Board Restructuring

Top High Growth Tech Stocks To Watch In September 2024
AUPH

Simply Wall St.

a year ago

Top High Growth Tech Stocks To Watch In September 2024

Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases
AUPH

Clinical Trials Arena

a year ago

Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
AUPH

Business Wire

a year ago

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
AUPH

Business Wire

a year ago

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
AUPH

Simply Wall St.

a year ago

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Do Options Traders Know Something About Aurinia (AUPH) Stock We Don't?
AUPH

Zacks

a year ago

Do Options Traders Know Something About Aurinia (AUPH) Stock We Don't?

Aurinia Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
AUPH

Simply Wall St.

a year ago

Aurinia Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations

Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates
AUPH

Zacks

a year ago

Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates

AUPH

Associated Press Finance

a year ago

Aurinia: Q2 Earnings Snapshot

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
AUPH

Business Wire

a year ago

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
AUPH

Business Wire

a year ago

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
AUPH

Zacks

a year ago

Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?

Aurinia to Participate in Upcoming Investor Healthcare Conferences
AUPH

Business Wire

a year ago

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) most popular amongst retail investors who own 54% of the shares, institutions hold 35%
AUPH

Simply Wall St.

a year ago

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) most popular amongst retail investors who own 54% of the shares, institutions hold 35%

Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
AUPH

Zacks

a year ago

Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?

Aurinia Announces 2024 Annual General Meeting Results
AUPH

Business Wire

a year ago

Aurinia Announces 2024 Annual General Meeting Results

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO For Now
AUPH

Simply Wall St.

a year ago

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO For Now

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
AUPH

Business Wire

a year ago

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
AUPH

Business Wire

a year ago

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

Aurinia Provides Update on Proxy Statement
AUPH

Business Wire

a year ago

Aurinia Provides Update on Proxy Statement

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
AUPH

Business Wire

a year ago

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 64%, as stock drops 9.5% this past week
AUPH

Simply Wall St.

a year ago

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 64%, as stock drops 9.5% this past week

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
AUPH

Business Wire

a year ago

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
AUPH

Business Wire

a year ago

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024

How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
AUPH

Zacks

a year ago

How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
AUPH

Business Wire

a year ago

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript
AUPH

Insider Monkey

a year ago

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript

Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
AUPH

Zacks

a year ago

Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates

AUPH

Associated Press Finance

a year ago

Aurinia: Q1 Earnings Snapshot

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
AUPH

Business Wire

a year ago

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results

Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
AUPH

Business Wire

a year ago

Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
AUPH

Business Wire

a year ago

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program

UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
AUPH

Business Wire

a year ago

UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
AUPH

Business Wire

a year ago

Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024

Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
AUPH

Business Wire

a year ago

Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference

When Will Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Breakeven?
AUPH

Simply Wall St.

a year ago

When Will Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Breakeven?

11 Oversold Biotech Stocks To Buy Right Now
AUPH

Insider Monkey

a year ago

11 Oversold Biotech Stocks To Buy Right Now

We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
AUPH

Simply Wall St.

2 years ago

We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

Share on Social Networks: